Fudan University affiliated Huashan Hospital Trials

Fudan University affiliated Huashan Hospital	Welcome, Profile Billing Logout

53 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Wenhong

HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting

640

RoW

Tenofovir Amibufenamide（TMF）, HS-10234

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Hepatitis B, Chronic

06/24

09/29

NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting

100

RoW

Tenofovir Alafenamide 25 MG, Vemlidy

New Discovery LLC, Beijing Ditan Hospital

Hepatitis B, Chronic

09/23

NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated

290

RoW

JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo

Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH

Moderate to Severe COVID-19

12/22

ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed

361

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Respiratory Viral Infection

02/25

NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated

2/3

381

RoW

JT001, VV116, Placebo

Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH

Mild to Moderate COVID-19

03/23

NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting

2/3

1188

RoW

FB2001, DC402234, FB2001 placebo

Frontier Biotechnologies Inc.

COVID-19

11/23

12/23

B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting

280

Europe, Canada, Japan, US, RoW

Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo

GlaxoSmithKline

Chronic Hepatitis B Virus Infection, Hepatitis B

07/27

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

Zhang, Jing

NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed

458

RoW

608 Q2W, 608 Q4W, Placebo, PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Psoriasis

10/23

06/24

NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting

360

Europe, US, RoW

Elamipretide, Elamipretide HCL, Placebo

Stealth BioTherapeutics Inc.

Age Related Macular Degeneration (ARMD)

08/26

08/27

ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed

361

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Respiratory Viral Infection

02/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting

120

RoW

TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Non-alcoholic Steatohepatitis

12/26

12/27

TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation

160

ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo

Alkeus Pharmaceuticals, Inc.

Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

06/26

11/26

NCT06962865: A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Not yet recruiting

RoW

RC108, RC108 For Injection；, Furmonertinib Mesilate Tablets Monotherapy, Furmonertinib

RemeGen Co., Ltd.

Non-Small Cell Lung Cancer

05/26

12/27

NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed

1/2

121

RoW

Genakumab for Injection, Placebo for Genakumab for Injection

Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University

Acute Gout

06/22

NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed

1/2

202

RoW

GR2001, Placebo, HTIG, Tetanus Toxoid

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Tetanus

11/23

02/24

NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed

1/2

US, RoW

IMP4297(senaparib), temozolomide

Impact Therapeutics, Inc.

Advanced Solid Tumours, Small Cell Lung Cancer

04/24

NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting

RoW

HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Similarity of Pharmacokinetics and Safety

12/21

NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed

RoW

ABSK021 with fed state, ABSK021 with fasted state

Abbisko Therapeutics Co, Ltd

Neoplasms

08/22

05/23

NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting

102

RoW

SYHX 1901 tablets, Placebo

CSPC Ouyi Pharmaceutical Co., Ltd.

Healthy Subjects

08/22

12/22

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed

RoW

IBI353 (Orismilast), placebo

Innovent Biologics (Suzhou) Co. Ltd.

Healthy Subjects

11/22

12/22

NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed

RoW

TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg

Vigonvita Life Sciences

Healthy Subjects

12/22

NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting

RoW

BAT4406F

Bio-Thera Solutions

Neuromyelitis Optica Spectrum Disorders

03/23

06/23

NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed

RoW

HS-10374 tablets, HS-10374-matched placebo tablets

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Psoriasis

03/23

NCT05511870: A Study of Etripamil in Healthy Subjects

Completed

RoW

Etripamil Nasal Spray 70mg, Placebo

Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.

Healthy Chinese Subjects

03/23

NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed

252

RoW

HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®

Shanghai Henlius Biotech

Healthy Male Volunteers

09/23

NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed

RoW

Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin

Abbisko Therapeutics Co, Ltd

Healthy Subjects

08/23

09/23

NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed

RoW

Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg

Vigonvita Life Sciences

Healthy Subjects

09/23

NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting

RoW

SG301 SC Injection, SG301 SC Placebo

Hangzhou Sumgen Biotech Co., Ltd.

Systemic Lupus Erythematosus (SLE)

05/25

10/25

NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting

RoW

JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts

Jemincare

Safety and Tolerability

12/23

03/24

SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting

SGB-9768, Placebo

Suzhou Sanegene Bio Inc.

Healthy Volunteer

05/25

10/25

NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated

RoW

SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection

Suzhou Erye Pharmaceutical Co., Ltd.

Infections

05/24

NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting

RoW

JMKX003801, Placebo

Jemincare

Healthy

05/25

06/25

NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting

RoW

0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Atopic Dermatitis

10/24

NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed

RoW

TAK-279, Placebo

Takeda

Healthy Volunteers

07/24

08/24

NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting

RoW

GenSci120, Placebo

Changchun GeneScience Pharmaceutical Co., Ltd.

Autoimmune Disease

01/26

04/26

Zou, Hejian

NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed

313

RoW

genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan

Changchun GeneScience Pharmaceutical Co., Ltd.

Acute Gout Arthritis

04/24

NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting

500

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Acute Gout

12/24

11/25

NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting

200

RoW

SHR-1314 injection, Placebo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Psoriatic Arthritis

04/26

06/26

NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting

225

RoW

Belimumab

GlaxoSmithKline, ICON plc

Bronchial Diseases

07/28

01/30

BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE

Recruiting

2/3

300

Europe, Japan, US, RoW

Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo

GlaxoSmithKline

Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

05/27

07/27

RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed

491

Europe, Canada, Japan, US, RoW

Peresolimab, Placebo

Eli Lilly and Company

Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases

11/23

01/25

Gensci 048-202, NCT05936281: A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Completed

165

RoW

Genakumab for injection, Colchicine

Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital

Gout, Gout Initiating Urate-loweringUrate-lowering Therapy

01/24

Gensci 048-203, NCT05936268: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Completed

106

RoW

Genakumab for injection, Colchicine

Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital

Acute Gout, Gout Flare

02/24

NCT06176508: Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Recruiting

160

RoW

HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral

Hansoh BioMedical R&D Company

Psoriatic Arthritis

04/26

08/26

NCT06270225: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Active, not recruiting

157

RoW

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, SSGJ-613 100mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200mg, Colchicine 0.5 mg

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Gout Arthritis

10/24

12/24

NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed

RoW

Febuxostat, IBI128

Innovent Biologics (Suzhou) Co. Ltd.

Gout, Hyperuricemia

12/24

01/25

NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed

1/2

121

RoW

Genakumab for Injection, Placebo for Genakumab for Injection

Acute Gout

06/22

NCT05588908: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Recruiting

1/2

120

RoW

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib), SSGJ-613 100 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib), SSGJ-613 200 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib), SSGJ-613 300 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II), SSGJ-613 200 mg (phase II), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II), SSGJ-613 300 mg (phase II), Compound Betamethasone Injection (phase II), Placebo (phase II), PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Acute Gout

09/23

11/23

Qin, Xiaoli

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

Wang, Le

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Wenhong

HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting

640

RoW

Tenofovir Amibufenamide（TMF）, HS-10234

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Hepatitis B, Chronic

06/24

09/29

NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting

100

RoW

Tenofovir Alafenamide 25 MG, Vemlidy

New Discovery LLC, Beijing Ditan Hospital

Hepatitis B, Chronic

09/23

NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated

290

RoW

JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo

Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH

Moderate to Severe COVID-19

12/22

ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed

361

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Respiratory Viral Infection

02/25

NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated

2/3

381

RoW

JT001, VV116, Placebo

Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH

Mild to Moderate COVID-19

03/23

NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting

2/3

1188

RoW

FB2001, DC402234, FB2001 placebo

Frontier Biotechnologies Inc.

COVID-19

11/23

12/23

B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting

280

Europe, Canada, Japan, US, RoW

Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo

GlaxoSmithKline

Chronic Hepatitis B Virus Infection, Hepatitis B

07/27

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

Zhang, Jing

NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed

458

RoW

608 Q2W, 608 Q4W, Placebo, PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Psoriasis

10/23

06/24

NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting

360

Europe, US, RoW

Elamipretide, Elamipretide HCL, Placebo

Stealth BioTherapeutics Inc.

Age Related Macular Degeneration (ARMD)

08/26

08/27

ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed

361

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Respiratory Viral Infection

02/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting

120

RoW

TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Non-alcoholic Steatohepatitis

12/26

12/27

TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation

160

ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo

Alkeus Pharmaceuticals, Inc.

Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

06/26

11/26

Not yet recruiting

RoW

RC108, RC108 For Injection；, Furmonertinib Mesilate Tablets Monotherapy, Furmonertinib

RemeGen Co., Ltd.

Non-Small Cell Lung Cancer

05/26

12/27

NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed

1/2

121

RoW

Genakumab for Injection, Placebo for Genakumab for Injection

Acute Gout

06/22

NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed

1/2

202

RoW

GR2001, Placebo, HTIG, Tetanus Toxoid

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Tetanus

11/23

02/24

NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed

1/2

US, RoW

IMP4297(senaparib), temozolomide

Impact Therapeutics, Inc.

Advanced Solid Tumours, Small Cell Lung Cancer

04/24

NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting

RoW

HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Similarity of Pharmacokinetics and Safety

12/21

NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed

RoW

ABSK021 with fed state, ABSK021 with fasted state

Abbisko Therapeutics Co, Ltd

Neoplasms

08/22

05/23

NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting

102

RoW

SYHX 1901 tablets, Placebo

CSPC Ouyi Pharmaceutical Co., Ltd.

Healthy Subjects

08/22

12/22

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed

RoW

IBI353 (Orismilast), placebo

Innovent Biologics (Suzhou) Co. Ltd.

Healthy Subjects

11/22

12/22

NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed

RoW

TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg

Vigonvita Life Sciences

Healthy Subjects

12/22

NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting

RoW

BAT4406F

Bio-Thera Solutions

Neuromyelitis Optica Spectrum Disorders

03/23

06/23

NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed

RoW

HS-10374 tablets, HS-10374-matched placebo tablets

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Psoriasis

03/23

NCT05511870: A Study of Etripamil in Healthy Subjects

Completed

RoW

Etripamil Nasal Spray 70mg, Placebo

Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.

Healthy Chinese Subjects

03/23

NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed

252

RoW

HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®

Shanghai Henlius Biotech

Healthy Male Volunteers

09/23

NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed

RoW

Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin

Abbisko Therapeutics Co, Ltd

Healthy Subjects

08/23

09/23

NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed

RoW

Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg

Vigonvita Life Sciences

Healthy Subjects

09/23

NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting

RoW

SG301 SC Injection, SG301 SC Placebo

Hangzhou Sumgen Biotech Co., Ltd.

Systemic Lupus Erythematosus (SLE)

05/25

10/25

NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting

RoW

JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts

Jemincare

Safety and Tolerability

12/23

03/24

SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting

SGB-9768, Placebo

Suzhou Sanegene Bio Inc.

Healthy Volunteer

05/25

10/25

NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated

RoW

SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection

Suzhou Erye Pharmaceutical Co., Ltd.

Infections

05/24

NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting

RoW

JMKX003801, Placebo

Jemincare

Healthy

05/25

06/25

NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting

RoW

0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Atopic Dermatitis

10/24

NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed

RoW

TAK-279, Placebo

Takeda

Healthy Volunteers

07/24

08/24

NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting

RoW

GenSci120, Placebo

Changchun GeneScience Pharmaceutical Co., Ltd.

Autoimmune Disease

01/26

04/26

Zou, Hejian

NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed

313

RoW

genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan

Changchun GeneScience Pharmaceutical Co., Ltd.

Acute Gout Arthritis

04/24

NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting

500

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Acute Gout

12/24

11/25

NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting

200

RoW

SHR-1314 injection, Placebo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Psoriatic Arthritis

04/26

06/26

NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting

225

RoW

Belimumab

GlaxoSmithKline, ICON plc

Bronchial Diseases

07/28

01/30

BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE

Recruiting

2/3

300

Europe, Japan, US, RoW

Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo

GlaxoSmithKline

Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

05/27

07/27

RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed

491

Europe, Canada, Japan, US, RoW

Peresolimab, Placebo

Eli Lilly and Company

Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases

11/23

01/25

Gensci 048-202, NCT05936281: A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Completed

165

RoW

Genakumab for injection, Colchicine

Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital

Gout, Gout Initiating Urate-loweringUrate-lowering Therapy

01/24

Gensci 048-203, NCT05936268: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Completed

106

RoW

Genakumab for injection, Colchicine

Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital

Acute Gout, Gout Flare

02/24

NCT06176508: Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Recruiting

160

RoW

HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral

Hansoh BioMedical R&D Company

Psoriatic Arthritis

04/26

08/26

NCT06270225: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Active, not recruiting

157

RoW

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, SSGJ-613 100mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200mg, Colchicine 0.5 mg

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Gout Arthritis

10/24

12/24

NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed

RoW

Febuxostat, IBI128

Innovent Biologics (Suzhou) Co. Ltd.

Gout, Hyperuricemia

12/24

01/25

NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed

1/2

121

RoW

Genakumab for Injection, Placebo for Genakumab for Injection

Acute Gout

06/22

NCT05588908: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Recruiting

1/2

120

RoW

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Acute Gout

09/23

11/23

Qin, Xiaoli

NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed

RoW

ZX-7101A, Placebo

Nanjing Zenshine Pharmaceuticals

Safety Issues, Tolerance, Pharmacokinetics, Food Effect

08/22

12/22

Wang, Le

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites